We are live on ! Find out more
BCM

Boone Capital Management Portfolio holdings

AUM $326M
1-Year Est. Return 86.31%
This Fund
S&P 500
This Quarter Est. Return
+28.61%
1 Year Est. Return
+86.31%
3 Year Est. Return
+255.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$494M
AUM Growth
+$66M
Cap. Flow
+$24.5M
Cap. Flow %
4.95%
Top 10 Hldgs %
67.93%
Holding
24
New
3
Increased
11
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$17.9M
2
CI icon
Cigna
CI
+$13.9M
3
VKTX icon
Viking Therapeutics
VKTX
+$13.8M
4
BERY
Berry Global Group, Inc.
BERY
+$13.5M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$12M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$29.2M
2
CVS icon
CVS Health
CVS
+$29M
3
BBIO icon
BridgeBio Pharma
BBIO
+$17.8M
4
DHR icon
Danaher
DHR
+$10.4M
5
VTRS icon
Viatris
VTRS
+$9.38M

Sector Composition

Rank Sector Weight
1 Healthcare 80.41%
2 Financials 11.12%
3 Materials 5.51%
4 Technology 2.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNM icon
1
Unum
UNM
$13.7B
$55M 11.12%
1,025,027
+63,366
+7% +$3.09M
CI icon
2
Cigna
CI
$75.1B
$47.9M 9.69%
131,926
+42,286
+47% +$13.9M
MOH icon
3
Molina Healthcare
MOH
$10.2B
$35.2M 7.12%
85,716
+17,428
+26% +$6.75M
ENOV icon
4
Enovis
ENOV
$1.66B
$35.1M 7.11%
562,739
– –
BAX icon
5
Baxter International
BAX
$13.5B
$29.8M 6.03%
697,957
+149,421
+27% +$6.08M
GMED icon
6
Globus Medical
GMED
$10.7B
$28.4M 5.75%
529,825
– –
BERY
7
DELISTED
Berry Global Group, Inc.
BERY
$27.2M 5.51%
490,160
+238,104
+94% +$13.5M
AMPH icon
8
Amphastar Pharmaceuticals
AMPH
$868M
$26.6M 5.39%
606,688
+206,688
+52% +$10.7M
VKTX icon
9
Viking Therapeutics
VKTX
$3.72B
$25.5M 5.15%
+310,462
New +$13.8M
BIO icon
10
Bio-Rad Laboratories Class A
BIO
$8.58B
$25M 5.06%
72,344
+36,631
+103% +$12M
IDYA icon
11
IDEAYA Biosciences
IDYA
$3.44B
$23.3M 4.72%
531,967
– –
TARS icon
12
Tarsus Pharmaceuticals
TARS
$2.53B
$22.1M 4.48%
+609,104
New +$17.9M
DHR icon
13
Danaher
DHR
$137B
$16.4M 3.32%
65,811
-42,690
-39% -$10.4M
MLAB icon
14
Mesa Laboratories
MLAB
$549M
$14.6M 2.96%
133,394
+69,330
+108% +$6.98M
OFIX icon
15
Orthofix Medical
OFIX
$467M
$14.1M 2.86%
974,502
+474,502
+95% +$6.56M
VTRS icon
16
Viatris
VTRS
$20.4B
$13.5M 2.74%
1,133,591
-778,681
-41% -$9.38M
XENE icon
17
Xenon Pharmaceuticals
XENE
$6.07B
$12.5M 2.54%
291,403
+35,971
+14% +$1.65M
HCSG icon
18
Healthcare Services Group
HCSG
$1.57B
$11.6M 2.34%
+926,455
New +$10.3M
MIRM icon
19
Mirum Pharmaceuticals
MIRM
$6.55B
$11.4M 2.3%
451,898
-38,241
-8% -$1.05M
PNTG icon
20
Pennant Group
PNTG
$1.4B
$11.1M 2.24%
564,192
+234,532
+71% +$3.95M
QTRX icon
21
Quanterix
QTRX
$160M
$7.78M 1.57%
330,151
-238,393
-42% -$5.91M
AMGN icon
22
Amgen
AMGN
$207B
– –
-101,508
Closed -$29.2M
BBIO icon
23
BridgeBio Pharma
BBIO
$15.6B
– –
-440,845
Closed -$17.8M
CVS icon
24
CVS Health
CVS
$135B
– –
-367,370
Closed -$29M

Similar funds

ISFAN
Investor's Fiduciary Advisor Network Snoqualmie, Washington $326M AUM 19.7% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
AFA
Alpha Financial Advisors Charlotte, North Carolina $326M AUM 15.49% 1-Year Est. Return
ECH
ER Collective Holdings Washington, District of Columbia $326M AUM
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
MVM
Menlo Ventures Management Menlo Park, California $327M AUM
CCG
Ceeto Capital Group Coral Gables, Florida $326M AUM 24.81% 1-Year Est. Return
TC
TFR Capital Plano, Texas $326M AUM 24.24% 1-Year Est. Return

Boone Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Boone Capital Management held 24 positions worth $494M, up 15% from $428M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Boone Capital Management deployed $24.5M of net new capital in Q1 2024, opening 3 new positions and adding to 11 existing holdings. Its largest new stake was Tarsus Pharmaceuticals: 609,104 shares worth $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Danaher, an estimated $10.4M trimmed.

  • Boone Capital Management's largest Q1 2024 buy was Tarsus Pharmaceuticals: 609,104 shares worth $22.1M.
  • Boone Capital Management added most to Cigna in Q1 2024, an estimated $13.9M increase.
  • Boone Capital Management's biggest Q1 2024 reduction was Danaher, cutting an estimated $10.4M.
  • Boone Capital Management fully exited Amgen in Q1 2024, selling an estimated $29.2M.
  • Boone Capital Management's ten largest holdings make up 68% of its $494M portfolio in Q1 2024.
  • Boone Capital Management opened 3 new positions and closed 3 in Q1 2024.
  • Boone Capital Management's portfolio value rose 15% quarter-over-quarter to $494M.

Based on Boone Capital Management's 13F filing for Q1 2024, filed 15 May 2024.